We have located links that may give you full text access.
CLINICAL TRIAL
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia].
The subjects of the study were 43 patients with II- III functional class coronary heart disease (CHD) and dyslipidemia, who received conventional cardial therapy. The patients were divided into two groups: group I (26 subjects) received vasilip, a simvastatin generic, in a dose of 20 mg a day; group 11 (17 subjects) received vasilip in a dose of 20 mg a day plus cudesan in a dose of 1 ml a day, which contained 30 mg of ubiquinone Q 10 and 4.5 mg of alpha-tocopherol. Effects of the therapies on blood lipids, their peroxides, and the antioxidative status of blood were studied. After one month, vasilip was effective in achieving the target level of low-density lipoprotein cholesterol in 62% of group I patients and 65% of group II patients; at the same time, its use led to a significant increase in the level of primary and secondary lipid peroxidation (LP) products (25% and 29%, respectively), and lowering of the antioxidative status of blood, which consisted in a decrease in ceruloplasmin (CP) serum level and CP: transferrin (CP:TF) ratio by 6% in group I patients. The use of cudesan in combination with vasilip led to a significant decrease in the level of primary and secondary LP products (30% and 29%, respectively), and an increase in the level of serum CP by 25.7%, and CP: TF ratio by 12.5%.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app